760 WEEKLY EPIDEMIOLOGICAL RECORD, NOS. 51/52, 20 DECEMBER 2024, pp.760-769. In French and English
The purpose of this guide is to provide practical advice for health staff undertaking infectious disease preparedness and response activities to ensure that access to safe abortion care (SAC) is maintained when an infectious disease outbreak occurs. It is an operational guide which can serve to supp...ort health actors to maintain SAC services during outbreaks and ensure that necessary SAC considerations are integrated within outbreak responses; it is not a clinical guide. The locational focus of this document is humanitarian and fragile settings; however, recommendations may apply to infectious disease outbreaks in all low-resource populations. This guide is intended to complement Sexual and Reproductive Health and Rights During Infectious Disease Outbreaks: Operational Guidance for Humanitarian and Fragile Settings.
more
Antimicrobial resistance(AMR) poses a serious threat to human, animal and environmental health. Implementing ethical practice guidelines on how to use antimicrobials effectively and responsibly within the pig industry will contribute in reducing and preventing antimicro...bial resistance within the pig industry of South Africa. Members of Pig Vet Society (PVS) SA hereby commit themselvesto put these guidelines into good use in order to preserve the future and effectiveness of antimicrobials. PVS aims to be the leader in prevention of antimicrobial resistance and to encourage the pig industry to work together in achieving this.
more
Anopheles stephensi, a highly competent vector of Plasmodium falciparum and P. vivax, is considered an efficient vector of urban malaria. Until 2011, the reported distribution of An. stephensi was confined to certain countries of South Asia and parts of the Arabian Peninsula. Since then, the vector ...has been collected in Djibouti (2012), Ethiopia (2016), Sudan (2016), Sri Lanka (2017), Somalia (2019), and most recently Nigeria (2020) and Yemen (2021). WHO considers the spread of An. stephensi to be a major potential threat to malaria control and elimination in Africa and southern Asia and has recently launched an initiative against the spread of this vector in Africa.
more
Since the notification of the first two confirmed cases of Vibrio cholerae O1 in the greater Port-au-Prince area on 2 October 2022, to 22 October 2022, the Haitian Ministry of Health (Ministère de la Santé Publique et de la Population, MSPP per its French acronym), reported a total of 2,243 suspec...ted cases, including 219 confirmed cases, 1,415 hospitalized suspected cases, and 55 registered deaths.
On 20 October 2022, the Dominican Republic Ministry of Public Health confirmed the first imported case of cholera in the country.
more
9 Febr. 2022
The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine specific requirements.
The Coronavirus is spreading globally. How can individuals, communities and humanitarian actors best respond to the COVID-19 outbreak? How can the Sphere Handbook guide our response?
These guidelines are available in different languages
Updated 8 June 2021. The document has two sections:
A. The first section covers fundamental principles which are crucial to a successful, holistic intervention.
B. The second covers relevant standards and guidance in the handbook’s Water Supply, Sanitation and Hygiene Promotion (WASH) and Health... chapters.
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
New England Journal of Medicine
April 9, 2021
DOI: 10.1056/NEJMoa2104840
The emergence and transmission of zoonotic diseases are driven by complex interactions
between health, environmental, and socio-political systems. Human movement is considered
a significant and increasing factor in these processes, yet forced migration remains an
understudied area of zoonotic res...earch–due in part to the complexity of conducting interdisciplinary
research in these settings.
more
This article is part four in a series of explainers on vaccine development and distribution
Available in different languages